Vanoxerine

Vanoxerine

Vanoexerine is a pharmacological compound that was initially developed for the treatment of cardiac arrhythmia. However, it has been repurposed and is currently being studied for its potential use in the treatment of drug addiction and Parkinson's disease.

History

Vanoexerine was first synthesized in the 1970s by the pharmaceutical company G.D. Searle & Company. It was initially developed as an antiarrhythmic drug, but its development was discontinued due to its potential to cause torsades de pointes, a type of life-threatening ventricular tachycardia.

Pharmacology

Vanoexerine is a potent and selective inhibitor of the dopamine transporter (DAT), which is responsible for the reuptake of dopamine in the brain. By blocking the reuptake of dopamine, vanoexerine increases the amount of dopamine available in the brain. This mechanism of action is similar to that of other drugs used in the treatment of Parkinson's disease and drug addiction.

Clinical Trials

In recent years, vanoexerine has been studied for its potential use in the treatment of drug addiction. In preclinical studies, it has been shown to reduce self-administration of cocaine and methamphetamine in animal models. Clinical trials are currently underway to evaluate the safety and efficacy of vanoexerine in humans with drug addiction.

Vanoexerine is also being studied for its potential use in the treatment of Parkinson's disease. In preclinical studies, it has been shown to have neuroprotective effects and to improve motor function in animal models of Parkinson's disease. Clinical trials are currently underway to evaluate the safety and efficacy of vanoexerine in humans with Parkinson's disease.

See Also

• Dopamine transporter
• Drug addiction
• Parkinson's disease

References

‎